Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older at the time of signing consent forms
• People diagnosed with a non-seminoma germ cell tumour, confirmed through tissue biopsy or blood tests
• People whose cancer came back after initial treatment with cisplatin-based chemotherapy
• People who have completed two cycles of high-dose chemotherapy with stem cell transplant as their second-line (salvage) treatment, following the guidelines of the treating institution
• High-dose chemotherapy must have been the first salvage treatment used, though one or two cycles of certain standard chemotherapy regimens beforehand may be acceptable (confirm with trial site)
• People whose tumour markers (AFP and hCG blood tests) are normal or falling at the time of screening
• People whose side effects from previous treatment have mostly resolved to a mild level by the time of registration
• Women with ovarian germ cell tumours are also eligible
• People with a general health and activity level rated as reasonably functional (scored 0, 1, or 2 on a standard medical scale), assessed within 28 days of joining the study
• People whose last high-dose chemotherapy dose was no more than 16 weeks before joining the study
• People whose blood counts, kidney, liver, and clotting function results fall within the required ranges, tested within 28 days before joining the study
• Women who could become pregnant must have a negative pregnancy test within 28 days before starting the study treatment
• Participants who are able to use two highly effective forms of contraception from the first dose of study treatment until 30 days after the last dose, or who abstain from heterosexual activity during that period

Who may not be able to join:

• People with a pure seminoma type of germ cell tumour that has relapsed
• People whose tumour markers (AFP and hCG) are rising at the time of screening
• People whose last high-dose chemotherapy dose was more than 16 weeks before the study registration date
• People who have received any other experimental treatment within 28 days before joining the study
• People who have had another active cancer requiring treatment in the past 12 months
• People with a history of psychiatric illness or personal circumstances that could make it difficult to follow the study requirements
• People with an active infection that requires treatment with antibiotics, antifungals, or other systemic medicines
• People who have previously had a serious allergic reaction to etoposide that did not improve with supportive care
• People who are pregnant, breastfeeding, or currently lactating
• People whose overall health, other medical conditions, or test results may interfere with the study results or make participation not in their best interest, as determined by the treating doctor

Important: Always verify eligibility with the trial site directly before applying.